Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms
Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from The UC Regents
medical device investing PathMaker Neurosystems Announces Publication of Scientific Paper Establishing First Linkage Between Spasticity and Overexpression of a Specific Neuronal Cotransporter
pharmaceutical investing Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for Parkinson’s Disease
pharmaceutical investing Cynapsus Therapeutics Up 115% on US$624 million Acquisition by Sunovion Pharmaceuticals
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
